The global psoriatic arthritis (PsA) treatment market is projected to exhibit strong growth through the forecast period, driven by the rising disease incidence and emergence of biosimilars. The competition is intensifying with innovator companies demanding stricter legal and regulatory guidelines.
Psoriatic arthritis is a chronic inflammatory condition of the skin and joints that gradually worsens with time. If left untreated, the disease may progress enough to cause permanent joint damage. Epidemiological data from the Arthritis Foundation suggests that more than 60% patients with psoriasis are susceptible to psoriatic arthritis.
The PsA treatment market has been segmented, on the basis of drug classes, into Nonsteroidal Antiinflammatory Drugs (NSAIDs), Disease-modifying Antirheumatic Drugs (DMARDs), and biologics. Among the aforementioned drug classes, biologics capture the largest market share, driven by their targeted mechanism of action and improved efficacy profiles.
The market is further segmented into topicals, orals, and injectables - on the basis of route of administration. Based on sales channel, the market is classified into prescription and Over-the-Counter (OTC) products. Geographically, the market has been divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa.
Some of the major players in the global psoriatic arthritis treatment market include AbbVie Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Johnson & Johnson Private Limited, Novartis International AG, Pfizer Inc., and UCB Pharma S.A.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."